| B62 | Pediatric ART regimen optimization in the midst of global supply chain challenges: lessons from implementation in Uganda | E-poster | ARV management strategies in paediatric and adolescent populations |
| B62 | HIV drug resistance patterns among highly treatment-experienced children, adolescents and young adults in sub-Saharan Africa | E-poster | ARV management strategies in paediatric and adolescent populations |
| B62 | The impact of the COVID-19 pandemic on uptake of multi-month dispensing (MMD) of antiretroviral therapy for children living with HIV: a multicountry analysis | E-poster | ARV management strategies in paediatric and adolescent populations |
| B62 | Impact of ARV optimization on HIV viral load suppression among children in Tanzania | E-poster | ARV management strategies in paediatric and adolescent populations |
| B62 | What are the drivers of improved viral suppression among HIV infected children (0-14 years)? Results from the national data warehouse in Kenya 2020 | E-poster | ARV management strategies in paediatric and adolescent populations |
| B61 | Once-daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children, Week 48 results of the SMILE PENTA-17 TRIAL | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | A randomised comparison of DTG-based ART vs standard of care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |